Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Laboratory of Cell Biology, Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Bethesda, MD 20892, USA.
Science. 2014 Sep 26;345(6204):1623-1627. doi: 10.1126/science.1255904. Epub 2014 Sep 11.
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibitory receptor found on immune cells. The consequences of mutations in CTLA4 in humans are unknown. We identified germline heterozygous mutations in CTLA4 in subjects with severe immune dysregulation from four unrelated families. Whereas Ctla4 heterozygous mice have no obvious phenotype, human CTLA4 haploinsufficiency caused dysregulation of FoxP3(+) regulatory T (Treg) cells, hyperactivation of effector T cells, and lymphocytic infiltration of target organs. Patients also exhibited progressive loss of circulating B cells, associated with an increase of predominantly autoreactive CD21(lo) B cells and accumulation of B cells in nonlymphoid organs. Inherited human CTLA4 haploinsufficiency demonstrates a critical quantitative role for CTLA-4 in governing T and B lymphocyte homeostasis.
细胞毒性 T 淋巴细胞相关抗原 4(CTLA-4)是一种在免疫细胞上发现的抑制性受体。人类 CTLA4 基因突变的后果尚不清楚。我们在四个无关联的家族中发现了严重免疫失调患者的 CTLA4 种系杂合突变。虽然 Ctla4 杂合子小鼠没有明显的表型,但人类 CTLA4 单倍不足导致 FoxP3(+)调节性 T(Treg)细胞失调、效应 T 细胞过度激活和靶器官淋巴细胞浸润。患者还表现出循环 B 细胞的进行性丧失,与主要自身反应性 CD21(lo)B 细胞增加和非淋巴器官 B 细胞积累有关。遗传性人类 CTLA4 单倍不足表明 CTLA-4 在调节 T 和 B 淋巴细胞稳态方面具有关键的定量作用。